|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eskander RN and Tewari KS: Targeting
angiogenesis in advanced cervical cancer. Ther Adv Med Oncol.
6:280–292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alonso S, González B, Ruiz-Larroya T,
Durán Domínguez M, Kato T, Matsunaga A, Suzuki K, Strongin AY,
Gimènez-Bonafé P and Perucho M: Epigenetic inactivation of the
extracellular matrix metallopeptidase ADAMTS19 gene and the
metastatic spread in colorectal cancer. Clin Epigenetics.
7:1242015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tseng RC, Chang JW, Mao JS, Tsai CD, Wu
PC, Lin CJ, Lu YL, Liao SY, Cheng HC, Hsu HS, et al:
Growth-arrest-specific 7C protein inhibits tumor metastasis via the
N-WASP/FAK/F-actin and hnRNP U/β-TrCP/β-catenin pathways in lung
cancer. Oncotarget. 6:44207–44221. 2015.PubMed/NCBI
|
|
5
|
Søes S, Daugaard IL, Sørensen BS, Carus A,
Mattheisen M, Alsner J, Overgaard J, Hager H, Hansen LL and
Kristensen LS: Hypomethylation and increased expression of the
putative oncogene ELMO3 are associated with lung cancer
development and metastases formation. Oncoscience. 1:367–374. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun W, Liu Y, Glazer CA, Shao C, Bhan S,
Demokan S, Zhao M, Rudek MA, Ha PK and Califano JA: TKTL1 is
activated by promoter hypomethylation and contributes to head and
neck squamous cell carcinoma carcinogenesis through increased
aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res.
16:857–866. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chesi M, Nardini E, Lim RS, Smith KD,
Kuehl WM and Bergsagel PL: The t(4;14) translocation in myeloma
dysregulates both FGFR3 and a novel gene, MMSET,
resulting in IgH/MMSET hybrid transcripts. Blood. 92:3025–3034.
1998.PubMed/NCBI
|
|
8
|
Lauring J, Abukhdeir AM, Konishi H, Garay
JP, Gustin JP, Wang Q, Arceci RJ, Matsui W and Park BH: The
multiple myeloma associated MMSET gene contributes to
cellular adhesion, clonogenic growth, and tumorigenicity. Blood.
111:856–864. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brito JL, Walker B, Jenner M, Dickens NJ,
Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE,
et al: MMSET deregulation affects cell cycle progression and
adhesion regulons in t(4;14) myeloma plasma cells. Haematologica.
94:78–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Toyokawa G, Cho HS, Masuda K, Yamane Y,
Yoshimatsu M, Hayami S, Takawa M, Iwai Y, Daigo Y, Tsuchiya E, et
al: Histone lysine methyltransferase Wolf-Hirschhorn syndrome
candidate 1 is involved in human carcinogenesis through regulation
of the Wnt pathway. Neoplasia. 13:887–898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang P, Guo L, Duan ZJ, Tepper CG, Xue L,
Chen X, Kung HJ, Gao AC, Zou JX and Chen HW: Histone
methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling
for cancer cell proliferation, survival, and tumor growth via a
feed-forward loop. Mol Cell Biol. 32:3121–3131. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kassambara A, Klein B and Moreaux J: MMSET
is overexpressed in cancers: Link with tumor aggressiveness.
Biochem Biophys Res Commun. 379:840–845. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hudlebusch HR, Santoni-Rugiu E, Simon R,
Ralfkiær E, Rossing HH, Johansen JV, Jørgensen M, Sauter G and
Helin K: The histone methyltransferase and putative oncoprotein
MMSET is overexpressed in a large variety of human tumors. Clin
Cancer Res. 17:2919–2933. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin A, Zhang Q, Kong X, Jia L, Yang Z,
Meng L, Li L, Wang X, Qiao Y, Lu N, et al: JAM3 methylation
status as a biomarker for diagnosis of preneoplastic and neoplastic
lesions of the cervix. Oncotarget. 6:44373–44387. 2015.PubMed/NCBI
|
|
15
|
Sood S, Patel FD, Ghosh S, Arora A,
Dhaliwal LK and Srinivasan R: Epigenetic alteration by DNA
methylation of ESR1, MYOD1 and hTERT gene
promoters is useful for prediction of response in patients of
locally advanced invasive cervical carcinoma treated by
chemoradiation. Clin Oncol. 27:720–727. 2015. View Article : Google Scholar
|
|
16
|
Gu C, Feng L, Peng H, Yang H, Feng Z and
Yang Y: MTDH is an oncogene in multiple myeloma, which is
suppressed by Bortezomib treatment. Oncotarget. 7:4559–4569.
2016.PubMed/NCBI
|
|
17
|
Zhang XY, Li M, Sun K, Chen XJ, Meng J, Wu
L, Zhang P, Tong X and Jiang WW: Decreased expression of GRIM-19 by
DNA hypermethylation promotes aerobic glycolysis and cell
proliferation in head and neck squamous cell carcinoma. Oncotarget.
6:101–115. 2015.PubMed/NCBI
|
|
18
|
Popovic R, Martinez-Garcia E, Giannopoulou
EG, Zhang Q, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small
EC, et al: Histone methyltransferase MMSET/NSD2 alters EZH2 binding
and reprograms the myeloma epigenome through global and focal
changes in H3K36 and H3K27 methylation. PLoS Genet.
10:e10045662014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ezponda T, Popovic R, Shah MY,
Martinez-Garcia E, Zheng Y, Min DJ, Will C, Neri A, Kelleher NL, Yu
J, et al: The histone methyltransferase MMSET/WHSC1 activates
TWIST1 to promote an epithelial-mesenchymal transition and invasive
properties of prostate cancer. Oncogene. 32:2882–2890. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Saloura V, Cho HS, Kiyotani K, Alachkar H,
Zuo Z, Nakakido M, Tsunoda T, Seiwert T, Lingen M, Licht J, et al:
WHSC1 promotes oncogenesis through regulation of NIMA-related
kinase-7 in squamous cell carcinoma of the head and neck. Mol
Cancer Res. 13:293–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang S, Zhang Y, Meng F, Liu Y, Xia B,
Xiao M, Xu Y, Ning X, Li H and Lou G: Overexpression of multiple
myeloma SET domain (MMSET) is associated with advanced tumor
aggressiveness and poor prognosis in serous ovarian carcinoma.
Biomarkers. 18:257–263. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou P, Wu LL, Wu KM, Jiang W, Li JD, Zhou
LD, Li XY, Chang S, Huang Y, Tan H, et al: Overexpression of MMSET
is correlation with poor prognosis in hepatocellular carcinoma.
Pathol Oncol Res. 19:303–309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiao M, Yang S, Chen J, Ning X, Guo L,
Huang K and Sui L: Overexpression of MMSET in endometrial cancer: A
clinicopathologic study. J Surg Oncol. 107:428–432. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hrabeta J, Eckschlager T, Stiborova M,
Heger Z, Krizkova S and Adam V: Zinc and zinc-containing
biomolecules in childhood brain tumors. J Mol Med (Berl).
94:1199–1215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Basset P, Bellocq JP, Wolf C, Stoll I,
Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC and Chambon
P: A novel metalloproteinase gene specifically expressed in stromal
cells of breast carcinomas. Nature. 348:699–704. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chabottaux V and Noel A: Breast cancer
progression: Insights into multifaceted matrix metalloproteinases.
Clin Exp Metastasis. 24:647–656. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: Biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Raithatha SA, Muzik H, Muzik H, Rewcastle
NB, Johnston RN, Edwards DR and Forsyth PA: Localization of
gelatinase-A and gelatinase-B mRNA and protein in human gliomas.
Neuro Oncol. 2:145–150. 2000. View Article : Google Scholar : PubMed/NCBI
|
